
    
      The comparative efficacy between imatinib dose escalation (600 mg QD) and nilotinib (400 mg
      BID), in terms of CCyR after 6 months, for patients with CML in chronic phase with suboptimal
      response to imatinib standard dose will be determined.
    
  